BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

20 articles for AV Mayweg

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.EBI
Roche Innovation Center Shanghai
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.EBI
Roche Pharma Research and Early Development (Pred)
ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.EBI
F. Hoffmann-La Roche
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.EBI
China Innovation Center of Roche
Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.EBI
TBA
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.EBI
Roche Innovation Center Shanghai
Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction.EBI
Roche Innovation Center Shanghai
Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.EBI
TBA
Discovery of potent and selective CDK8 inhibitors through FBDD approach.EBI
Roche Innovation Center Shanghai
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.BDB
Novartis Institutes For Biomedical Research
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenaseBDB
Incyte
Inhibition of the Flavin-Dependent Monooxygenase Siderophore A (SidA) Blocks Siderophore Biosynthesis and Aspergillus fumigatus Growth.BDB
Virginia Tech
Design and characterization of bivalent BET inhibitors.BDB
Dana-Farber Cancer Institute
Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitorsBDB
Merck Sharp & Dohme
Glucagon receptor antagonists, preparation and therapeutic usesBDB
Eli Lilly
Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.BDB
University of Colorado Denver
Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.BDB
University of Tours